首页 | 本学科首页   官方微博 | 高级检索  
     

放射联合顺铂治疗鼻咽癌的前瞻性临床研究
引用本文:郭小毛,刘瑛,何少琴. 放射联合顺铂治疗鼻咽癌的前瞻性临床研究[J]. 中华肿瘤防治杂志, 1996, 0(4)
作者姓名:郭小毛  刘瑛  何少琴
作者单位:上海医科大学附属肿瘤医院放疗科
摘    要:98例己确诊为鼻咽癌病例随机分为单纯放射组(48例)和放射治疗综合应用顺铂组(50例)。放射治疗全部采用同中心治疗,总剂量70Gy/35-37次/7—8周。顺铂自放射开始后第二天使用,1次/周,20mg/m2/次。在治疗结束后三月评价,放射联合顺铂组和单纯放射组的原发肿瘤完全消退率分别为92%和68.75%,颈部转移灶的完全消退率分别为90.6%和69.4%,两组经统计学处理均有显著性差异。随访三年(中位随访期40月),三年生存率分别为综合治疗组83%和单纯放射射组76%。两组急性反应和后期反应无显著差异,所有病人均能耐受而完成治疗计划。

关 键 词:鼻咽癌  放射治疗  顺铂

Prospective Randomized Trial of Radiotherapy plus Cisp latin ( CDDP) for Nasopharyngeal Carcinoma
Guo xiaomao Liu yin He Sh aoqin,et al. Prospective Randomized Trial of Radiotherapy plus Cisp latin ( CDDP) for Nasopharyngeal Carcinoma[J]. Chinese Journal of Cancer Prevention and Treatment, 1996, 0(4)
Authors:Guo xiaomao Liu yin He Sh aoqin  et al
Affiliation:Cancer Hospital. Shanghai Medical University.Shanghai 200032
Abstract:98 patients with nasopharyngeal carcioma were randomized Single radiotherapy group(Arml.48 cases) and radiotherapy plus CDDP Group (Arm2.50 cases).Radiotherapy was isocentry treatment for all patients and the total doses of 70GY/35-37 fractions / 7-8 weeks.The cisplatin was given 20mg/m 2 once a week for 7-8 weeks. The results was that patients in arm2 had higher CR rate than in Arm l.Followed up three years (median 40 months) the three years survival rate was 76% in Arm l and 83% in Arm 2.The acute reaction and the late reaction were more severe in Arm2 than that observed in Arm l, but all were tolerable.
Keywords:Nasopharyngeal Carcinoma Radiotherapy Cisplatin  
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号